Outcome of COVID-19 infection in 50 multiple myeloma patients
treated with novel drugs: single-center experience

J 2021

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

KREJČÍ, Marta, Luděk POUR, Zdeněk ADAM, Viera SANDECKÁ, Martin ŠTORK et. al.

Základní údaje

Originální název

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

Autoři

KREJČÍ, Marta (203 Česká republika, garant, domácí), Luděk POUR (203 Česká republika, domácí), Zdeněk ADAM (203 Česká republika, domácí), Viera SANDECKÁ (703 Slovensko, domácí), Martin ŠTORK (203 Česká republika, domácí), Sabina ŠEVČÍKOVÁ (203 Česká republika, domácí), Martin KREJČÍ (203 Česká republika, domácí), Zdeňka KNECHTOVÁ (203 Česká republika) a Zdeněk KRÁL (203 Česká republika, domácí)

Vydání

Annals of hematology, New York, Springer Verlag, 2021, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.030

Kód RIV

RIV/00216224:14110/21:00122810

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00277-021-04594-w

UT WoS

000678464700001

Klíčová slova anglicky

Multiple myeloma; COVID-19; Novel drugs; Hospitalization; Mortality

Štítky

14110212, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 10. 2022 17:53, Mgr. Tereza Miškechová

Anotace

V originále

Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus >= 3 (p = 0.014), presence of comorbidities (0-1 versus >= 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus >= 3 (p = 0.001), presence of comorbidities (0-1 versus >= 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.

Citovat

KREJČÍ, Marta, Luděk POUR, Zdeněk ADAM, Viera SANDECKÁ, Martin ŠTORK, Sabina ŠEVČÍKOVÁ, Martin KREJČÍ, Zdeňka KNECHTOVÁ a Zdeněk KRÁL. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Annals of hematology. New York: Springer Verlag, 2021, roč. 100, č. 10, s. 2541-2546. ISSN 0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-021-04594-w.

@article{1802378,
   author = {Krejčí, Marta and Pour, Luděk and Adam, Zdeněk and Sandecká, Viera and Štork, Martin and Ševčíková, Sabina and Krejčí, Martin and Knechtová, Zdeňka and Král, Zdeněk},
   article_location = {New York},
   article_number = {10},
   doi = {http://dx.doi.org/10.1007/s00277-021-04594-w},
   keywords = {Multiple myeloma; COVID-19; Novel drugs; Hospitalization; Mortality},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience},
   url = {https://link.springer.com/article/10.1007%2Fs00277-021-04594-w},
   volume = {100},
   year = {2021}
}

TY  - JOUR
ID  - 1802378
AU  - Krejčí, Marta - Pour, Luděk - Adam, Zdeněk - Sandecká, Viera - Štork, Martin - Ševčíková, Sabina - Krejčí, Martin - Knechtová, Zdeňka - Král, Zdeněk
PY  - 2021
TI  - Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
JF  - Annals of hematology
VL  - 100
IS  - 10
SP  - 2541-2546
EP  - 2541-2546
PB  - Springer Verlag
SN  - 09395555
KW  - Multiple myeloma
KW  - COVID-19
KW  - Novel drugs
KW  - Hospitalization
KW  - Mortality
UR  - https://link.springer.com/article/10.1007%2Fs00277-021-04594-w
N2  - Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus >= 3 (p = 0.014), presence of comorbidities (0-1 versus >= 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus >= 3 (p = 0.001), presence of comorbidities (0-1 versus >= 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.
ER  -

KREJČÍ, Marta, Luděk POUR, Zdeněk ADAM, Viera SANDECKÁ, Martin ŠTORK, Sabina ŠEVČÍKOVÁ, Martin KREJČÍ, Zdeňka KNECHTOVÁ a Zdeněk KRÁL. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. \textit{Annals of hematology}. New York: Springer Verlag, 2021, roč.~100, č.~10, s.~2541-2546. ISSN~0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-021-04594-w.

Podrobný výpis o publikaci